Thursday, 24 April 2014

Can a Selective PPAR? Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?

INT131 demonstrated dose-dependent reductions in HbA1c, equivalent to 45 mg pioglitazone, but with less fluid accumulation and weight gain, consistent with its SPPARM design (Diabetes Care)

Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes

Statins use is associated with increased HbA1c levels among hypertensive patients and hypertensive patients with diabetes. Clinicians managing hypertensive patients on statins should consider monitoring the HbA1c level and ensure that those with diabetes have their hyperglycaemia kept under control (Diabetology & Metabolic Syndrome)

The Patient Perspective of Diabetes Care: A Systematic Review of Stated Preference Research

The goal of this study was to examine how stated preference methods are applied in diabetes care, and to evaluate the value of this information in developing the patient perspective in clinical and policy decisions. (The Patient - Patient-Centered Outcomes Research)

Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein

High dp-ucMGP levels were independently associated with below-knee arterial calcification score in patients with type 2 diabetes and normal or slightly altered kidney function. The reversibility of the elevation of dp-ucMGP levels and the latter's relationship with clinical events merit further investigation (Cardiovascular Diabetology)

No comments:

Post a Comment